Sequential 5-Aza 2′-deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cells

[1]  U. Pendurthi,et al.  Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration. , 2004, Blood.

[2]  W. Kisiel,et al.  The effect of human tissue factor pathway inhibitor-2 on the growth and metastasis of fibrosarcoma tumors in athymic mice. , 2004, Blood.

[3]  G. Nicolson,et al.  In vitro modulation of human lung cancer cell line invasiveness by antisense cDNA of tissue factor pathway inhibitor-2 , 2004, Clinical & Experimental Metastasis.

[4]  G. Nicolson,et al.  Role of tissue factor pathway inhibitor-2 (TFPI-2) in amelanotic melanoma (C-32) invasion , 2004, Clinical & Experimental Metastasis.

[5]  M. Szyf,et al.  Valproate Induces Replication-independent Active DNA Demethylation* , 2003, Journal of Biological Chemistry.

[6]  K. Srivenugopal,et al.  Promoter methylation and silencing of the tissue factor pathway inhibitor-2 (TFPI-2), in human glioma cells , 2003, Oncogene.

[7]  M. Whiteway,et al.  The ERK/MAPK Pathway Regulates the Activity of the Human Tissue Factor Pathway Inhibitor-2 Promoter* , 2003, The Journal of Biological Chemistry.

[8]  Peter A. Jones,et al.  Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. , 2002, Blood.

[9]  Gillian Murphy,et al.  Metalloproteinase inhibitors: biological actions and therapeutic opportunities , 2002, Journal of Cell Science.

[10]  J. Minna,et al.  The expression of DNA methyltransferases and methyl-CpG-binding proteins is not associated with the methylation status of p14ARF, p16INK4a and RASSF1A in human lung cancer cell lines , 2002, Oncogene.

[11]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[12]  L. Neckers,et al.  Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. , 2002, Journal of the National Cancer Institute.

[13]  R. Hruban,et al.  Aberrant CpG island methylation in cancer cell lines arises in the primary cancers from which they were derived , 2002, Oncogene.

[14]  G. Kouraklis,et al.  Minimal and inducible regulation of tissue factor pathway inhibitor-2 in human gliomas , 2002, Oncogene.

[15]  Vigushin Dm,et al.  Histone deacetylase inhibitors in cancer treatment. , 2002 .

[16]  G. Bae,et al.  Activation of p21WAF1/Cip1 Transcription through Sp1 Sites by Histone Deacetylase Inhibitor Apicidin , 2001, The Journal of Biological Chemistry.

[17]  M. Szyf,et al.  Demethylase Activity Is Directed by Histone Acetylation* , 2001, The Journal of Biological Chemistry.

[18]  C. N. Rao,et al.  A novel function of tissue factor pathway inhibitor-2 (TFPI-2) in human glioma invasion , 2001, Oncogene.

[19]  P. Parsons,et al.  Histone Hyperacetylation Induced by Histone Deacetylase Inhibitors Is Not Sufficient to Cause Growth Inhibition in Human Dermal Fibroblasts* , 2001, The Journal of Biological Chemistry.

[20]  Keith D Robertson,et al.  DNA methylation, methyltransferases, and cancer , 2001, Oncogene.

[21]  P. Libby,et al.  Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. , 2001, The Journal of clinical investigation.

[22]  F. Marincola,et al.  Sequential 5-Aza-2′-deoxycytidine-Depsipeptide FR901228 Treatment Induces Apoptosis Preferentially in Cancer Cells and Facilitates Their Recognition by Cytolytic T Lymphocytes Specific for NY-ESO-1 , 2001, Journal of immunotherapy.

[23]  Julie A Hong,et al.  Induction of MAGE-3 expression in lung and esophageal cancer cells. , 2001, The Annals of thoracic surgery.

[24]  P. Marks,et al.  Histone deacetylase 4 associates with extracellular signal-regulated kinases 1 and 2, and its cellular localization is regulated by oncogenic Ras. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[25]  C. Heldin,et al.  Binding of factor VIIa to tissue factor on human fibroblasts leads to activation of phospholipase C and enhanced PDGF-BB-stimulated chemotaxis. , 2000, Blood.

[26]  W. Kisiel,et al.  Paradoxical Pro-invasive Effect of the Serine Proteinase Inhibitor Tissue Factor Pathway Inhibitor-2 on Human Hepatocellular Carcinoma Cells* , 2000, The Journal of Biological Chemistry.

[27]  M. Yoshida,et al.  Mechanism of cell cycle arrest caused by histone deacetylase inhibitors in human carcinoma cells. , 2000, The Journal of antibiotics.

[28]  C. N. Rao,et al.  Prokaryotic expression, purification, and reconstitution of biological activities (Antiprotease, antitumor, and heparin-binding) for tissue factor pathway inhibitor-2. , 2000, Biochemical and biophysical research communications.

[29]  J. Stam,et al.  Factor VIIa/Tissue Factor-induced Signaling via Activation of Src-like Kinases, Phosphatidylinositol 3-Kinase, and Rac* , 2000, The Journal of Biological Chemistry.

[30]  P. Marks,et al.  Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[31]  E. Sausville,et al.  P21-dependent G 1 arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228 , 2000, British Journal of Cancer.

[32]  C. Ponting,et al.  Regulation of chromatin structure by site-specific histone H3 methyltransferases , 2000, Nature.

[33]  P. Marks,et al.  Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. , 2000, Journal of the National Cancer Institute.

[34]  W. Kisiel,et al.  Nucleotide Sequence of the Gene Encoding Murine Tissue Factor Pathway Inhibitor-2 , 2000, Thrombosis and Haemostasis.

[35]  C. N. Rao,et al.  Matrix localization of tissue factor pathway inhibitor-2/matrix-associated serine protease inhibitor (TFPI-2/MSPI) involves arginine-mediated ionic interactions with heparin and dermatan sulfate: heparin accelerates the activity of TFPI-2/MSPI toward plasmin. , 1999, Archives of biochemistry and biophysics.

[36]  P. Nawroth,et al.  Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[37]  S. Sasayama,et al.  Tissue Factor Pathway Inhibitor-2 Is a Novel Mitogen for Vascular Smooth Muscle Cells* , 1999, The Journal of Biological Chemistry.

[38]  C. N. Rao,et al.  Regulation of ProMMP-1 and ProMMP-3 activation by tissue factor pathway inhibitor-2/matrix-associated serine protease inhibitor. , 1999, Biochemical and biophysical research communications.

[39]  M. Yoshida,et al.  FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. , 1998, Experimental cell research.

[40]  W. Ruf,et al.  Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis. , 1998, The Journal of clinical investigation.

[41]  L. Poulsen,et al.  Signal Transduction via the Mitogen-activated Protein Kinase Pathway Induced by Binding of Coagulation Factor VIIa to Tissue Factor* , 1998, The Journal of Biological Chemistry.

[42]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[43]  R. Jaenisch,et al.  Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[44]  W. Kisiel,et al.  Molecular cloning, expression, and partial characterization of a second human tissue-factor-pathway inhibitor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[45]  T S Edgington,et al.  Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[46]  W. Kisiel,et al.  Occurrence of blood coagulation factors in situ in small cell carcinoma of the lung , 1987, Cancer.